Brazil Study of 43K Adults Reveals GLP-1s Blood Pressure Effects

A new analysis of over 43,000 adults is giving researchers a clearer view of how GLP-1 drugs affect blood pressure, independent of their well-known effects on weight.

The meta-analysis, presented at the European Congress on Obesity in May 2026, reviewed 32 phase 3 clinical trials. The average participant was 54 years old, and about 59% had high blood pressure at the start. Participants took GLP-1 medications for an average of about 15 months.

Researchers found that for every 1% of body weight lost, participants saw a corresponding drop in their systolic blood pressure reading, the upper number in a blood pressure measurement. The more weight someone lost, the more their blood pressure dropped. This link held true regardless of the study’s length, the participant’s starting weight, sex, or whether they had diabetes.

Beyond weight loss

The connection between excess weight and high blood pressure is well known. This analysis quantifies that link in the context of GLP-1 drugs. A 2024 analysis of three large clinical trials found that semaglutide, the active ingredient in Ozempic and Wegovy, meaningfully lowered the upper number in blood pressure readings compared to a placebo. The results were consistent even in people who already had high blood pressure.

Another 2024 review of 15 trials found similar blood pressure improvements alongside significant weight loss in people taking GLP-1 drugs. A 2023 analysis of 61 clinical trials found that semaglutide produced the greatest blood pressure reduction of any medication studied.

Researchers note that even without weight loss, these drugs may directly relax blood vessels, improve kidney salt handling, and reduce stress signals in the body. All of these things can independently lower blood pressure. This means GLP-1 drugs may work through two pathways: a weight-dependent route, where losing weight lowers blood pressure, and a weight-independent route that acts directly on the cardiovascular and renal systems.

This second pathway is still being studied, but its existence helps explain why some patients see blood pressure benefits that seem larger than what their weight loss alone would suggest. The newer MHRMs, which target multiple hormone receptors at once, add another layer of complexity. Researchers are still working to untangle which mechanisms are driving which effects.

Clinical relevance

Obesity and hypertension reinforce each other. They are converging public health crises that contribute to preventable cardiovascular disease and deaths. Clinical guidelines already support managing overweight and obesity as a central strategy for blood pressure reduction.

For the roughly 59% of trial participants already living with hypertension, the blood pressure-lowering effect of these drugs was a clinically meaningful outcome. For people on these medications primarily for weight loss, understanding this cardiovascular dimension adds context to the full picture of what these drugs do in the body.

Study limitations

The meta-analysis has limitations. It relied on trial-level data rather than individual patient-level data. There was variability across trials in populations and study design. Blood pressure was not the primary outcome in any of the included trials. Patients may have also changed their antihypertension medications, which could have affected results.

Several trials are currently underway to investigate these effects further, including studies that focus on the acute effects these drugs have on cardiac and vascular function, kidney physiology, and neurohormonal pathways. The consistency of findings across 32 trials and more than 43,000 participants is hard to dismiss.

GLP-1 receptor agonists and next-generation obesity drugs are already reshaping how doctors think about weight management. This new meta-analysis adds another dimension, revealing they may also be meaningful tools for blood pressure management. This is particularly relevant for the large overlap of people living with both obesity and hypertension.